Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group Academic Article uri icon

Overview

MeSH Major

  • Bone Neoplasms
  • Cardiotonic Agents
  • Dexrazoxane
  • Osteosarcoma

abstract

  • Dexrazoxane cardioprotection was safely administered. It did not impair tumor response or increase the risk of secondary malignancy. Dexrazoxane allowed for therapeutic intensification increasing the cumulative doxorubicin dose in SR to induction chemotherapy. These findings support the use of dexrazoxane in children and adolescents with osteosarcoma.

publication date

  • January 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4779061

Digital Object Identifier (DOI)

  • 10.1002/pbc.25753

PubMed ID

  • 26398490

Additional Document Info

start page

  • 54

end page

  • 61

volume

  • 63

number

  • 1